• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种5基因特征与肿瘤免疫微环境密切相关并可预测非小细胞肺癌患者的预后。

A 5-Gene Signature Is Closely Related to Tumor Immune Microenvironment and Predicts the Prognosis of Patients with Non-Small Cell Lung Cancer.

机构信息

Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.

Institute of Physiological Chemistry and Pathobiochemistry, University of Muenster, Münster 48149, Germany.

出版信息

Biomed Res Int. 2020 Jan 10;2020:2147397. doi: 10.1155/2020/2147397. eCollection 2020.

DOI:10.1155/2020/2147397
PMID:31998783
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6975218/
Abstract

PURPOSE

Establishing prognostic gene signature to predict clinical outcomes and guide individualized adjuvant therapy is necessary. Here, we aim to establish the prognostic efficacy of a gene signature that is closely related to tumor immune microenvironment (TIME).

METHODS AND RESULTS

There are 13,035 gene expression profiles from 130 tumor samples of the non-small cell lung cancer (NSCLC) in the data set GSE103584. A 5-gene signature was identified by using univariate survival analysis and Least Absolute Shrinkage and Selection Operator (LASSO) to build risk models. Then, we used the CIBERSORT method to quantify the relative levels of different immune cell types in complex gene expression mixtures. It was found that the ratio of dendritic cells (DCs) activated and mast cells (MCs) resting in the low-risk group was higher than that in the high-risk group, and the difference was statistically significant ( < 0.001 and < 0.001 and < 0.001 and < 0.001 and < 0.001 and < 0.001 and < 0.001 and < 0.001 and < 0.001 and < 0.001 and < 0.001 and < 0.001 and.

CONCLUSION

The 5-gene signature is a powerful and independent predictor that could predict the prognosis of NSCLC patients. In addition, our gene signature is correlated with TIME parameters, such as DCs activated and MCs resting. Our findings suggest that the 5-gene signature closely related to TIME could predict the prognosis of NSCLC patients and provide some reference for immunotherapy.

摘要

目的

建立预后基因特征以预测临床结果并指导个体化辅助治疗很有必要。在此,我们旨在建立与肿瘤免疫微环境(TIME)密切相关的基因特征的预后效能。

方法与结果

数据集GSE103584中有来自130例非小细胞肺癌(NSCLC)肿瘤样本的13035个基因表达谱。通过单变量生存分析和最小绝对收缩和选择算子(LASSO)确定了一个5基因特征以构建风险模型。然后,我们使用CIBERSORT方法量化复杂基因表达混合物中不同免疫细胞类型的相对水平。发现低风险组中活化树突状细胞(DCs)与静息肥大细胞(MCs)的比例高于高风险组,差异具有统计学意义(<0.001和<0.001和<0.001和<0.001和<0.001和<0.001和<0.001和<0.001和<0.001和<0.001和<0.001和<0.001和。(注:原文此处部分重复的<0.001表述似乎有误,未完整呈现正确内容)

结论

5基因特征是一种强大且独立的预测指标,可预测NSCLC患者的预后。此外,我们的基因特征与TIME参数相关,如活化的DCs和静息的MCs。我们的研究结果表明,与TIME密切相关的5基因特征可预测NSCLC患者的预后,并为免疫治疗提供一些参考。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2840/6975218/0b180d693b14/BMRI2020-2147397.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2840/6975218/024d62348509/BMRI2020-2147397.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2840/6975218/04150b46374d/BMRI2020-2147397.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2840/6975218/75105ff89046/BMRI2020-2147397.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2840/6975218/df762f67f423/BMRI2020-2147397.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2840/6975218/0b180d693b14/BMRI2020-2147397.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2840/6975218/024d62348509/BMRI2020-2147397.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2840/6975218/04150b46374d/BMRI2020-2147397.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2840/6975218/75105ff89046/BMRI2020-2147397.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2840/6975218/df762f67f423/BMRI2020-2147397.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2840/6975218/0b180d693b14/BMRI2020-2147397.005.jpg

相似文献

1
A 5-Gene Signature Is Closely Related to Tumor Immune Microenvironment and Predicts the Prognosis of Patients with Non-Small Cell Lung Cancer.一种5基因特征与肿瘤免疫微环境密切相关并可预测非小细胞肺癌患者的预后。
Biomed Res Int. 2020 Jan 10;2020:2147397. doi: 10.1155/2020/2147397. eCollection 2020.
2
A signature of tumor immune microenvironment genes associated with the prognosis of non‑small cell lung cancer.与非小细胞肺癌预后相关的肿瘤免疫微环境基因特征
Oncol Rep. 2020 Mar;43(3):795-806. doi: 10.3892/or.2020.7464. Epub 2020 Jan 14.
3
Identification and Validation of a Tumor Microenvironment-Related Gene Signature for Prognostic Prediction in Advanced-Stage Non-Small-Cell Lung Cancer.鉴定和验证与肿瘤微环境相关的基因签名,用于晚期非小细胞肺癌的预后预测。
Biomed Res Int. 2021 Mar 30;2021:8864436. doi: 10.1155/2021/8864436. eCollection 2021.
4
Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.早期非鳞状非小细胞肺癌个体化免疫预后标志物的建立与验证。
JAMA Oncol. 2017 Nov 1;3(11):1529-1537. doi: 10.1001/jamaoncol.2017.1609.
5
Gene co-expression modules integrated with immunoscore predicts survival of non-small cell lung cancer.基因共表达模块与免疫评分相结合预测非小细胞肺癌的生存。
Cancer Treat Res Commun. 2021;26:100297. doi: 10.1016/j.ctarc.2020.100297. Epub 2020 Dec 25.
6
A robust signature associated with patient prognosis and tumor immune microenvironment based on immune-related genes in lung squamous cell carcinoma.基于肺鳞癌免疫相关基因的与患者预后和肿瘤免疫微环境相关的稳健标志物。
Int Immunopharmacol. 2020 Nov;88:106856. doi: 10.1016/j.intimp.2020.106856. Epub 2020 Aug 7.
7
Identification and Prognostic Value Exploration of Radiotherapy Sensitivity-Associated Genes in Non-Small-Cell Lung Cancer.识别和探索非小细胞肺癌放疗敏感性相关基因及其预后价值。
Biomed Res Int. 2021 Sep 2;2021:5963868. doi: 10.1155/2021/5963868. eCollection 2021.
8
Immune signature of T follicular helper cells predicts clinical prognostic and therapeutic impact in lung squamous cell carcinoma.T 滤泡辅助细胞的免疫特征可预测肺鳞状细胞癌的临床预后和治疗影响。
Int Immunopharmacol. 2020 Apr;81:105932. doi: 10.1016/j.intimp.2019.105932. Epub 2019 Dec 10.
9
The Combined Detection of Immune Genes for Predicting the Prognosis of Patients With Non-Small Cell Lung Cancer.免疫基因联合检测预测非小细胞肺癌患者预后
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820977504. doi: 10.1177/1533033820977504.
10
Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.肺腺癌中基于五个免疫检查点基因(IL(R))的表达signature 的临床意义和免疫图谱
Front Immunol. 2021 Aug 23;12:693062. doi: 10.3389/fimmu.2021.693062. eCollection 2021.

引用本文的文献

1
Radiogenomics models for predicting prognosis in locally advanced non-small cell lung cancer patients undergoing definitive chemoradiotherapy.用于预测接受根治性放化疗的局部晚期非小细胞肺癌患者预后的放射基因组学模型。
Transl Lung Cancer Res. 2024 Aug 31;13(8):1828-1840. doi: 10.21037/tlcr-24-145. Epub 2024 Aug 28.
2
Prognostic correlation between specialized capillary endothelial cells and lung adenocarcinoma.特殊毛细血管内皮细胞与肺腺癌之间的预后相关性
Heliyon. 2024 Mar 16;10(6):e28236. doi: 10.1016/j.heliyon.2024.e28236. eCollection 2024 Mar 30.
3
A new immune signature for survival prediction and immune checkpoint molecules in non-small cell lung cancer.

本文引用的文献

1
Emerging therapies for non-small cell lung cancer.新兴疗法治疗非小细胞肺癌。
J Hematol Oncol. 2019 Apr 25;12(1):45. doi: 10.1186/s13045-019-0731-8.
2
Molecular characterization of clinical responses to PD-1/PD-L1 inhibitors in non-small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD-1 inhibitors in Chinese patients.PD-1/PD-L1 抑制剂治疗非小细胞肺癌的临床反应的分子特征:多维免疫标志物检测对中国患者 PD-1 抑制剂疗效的预测价值。
Thorac Cancer. 2019 May;10(5):1303-1309. doi: 10.1111/1759-7714.13078. Epub 2019 Apr 23.
3
Beyond PD-L1 Markers for Lung Cancer Immunotherapy.
一种用于非小细胞肺癌生存预测和免疫检查点分子的新免疫特征。
Front Oncol. 2023 Jan 30;13:1095313. doi: 10.3389/fonc.2023.1095313. eCollection 2023.
4
Novel pyroptosis-associated genes signature for predicting the prognosis of sarcoma and validation.新型焦亡相关基因特征可预测肉瘤的预后及验证。
Biosci Rep. 2022 Dec 22;42(12). doi: 10.1042/BSR20221053.
5
Integrating Radiomics with Genomics for Non-Small Cell Lung Cancer Survival Analysis.整合放射组学与基因组学用于非小细胞肺癌生存分析
J Oncol. 2022 Aug 27;2022:5131170. doi: 10.1155/2022/5131170. eCollection 2022.
6
Construction and validation of a nomogram based on N6-Methylandenosine-related lncRNAs for predicting the prognosis of non-small cell lung cancer patients.基于 N6-甲基腺苷相关 lncRNAs 的列线图构建与验证用于预测非小细胞肺癌患者的预后。
Cancer Med. 2023 Jan;12(2):2058-2074. doi: 10.1002/cam4.4961. Epub 2022 Jun 21.
7
Predicting Differences in Treatment Response and Survival Time of Lung Adenocarcinoma Patients Based on a Prognostic Risk Model of Glycolysis-Related Genes.基于糖酵解相关基因预后风险模型预测肺腺癌患者治疗反应和生存时间的差异
Front Genet. 2022 May 25;13:828543. doi: 10.3389/fgene.2022.828543. eCollection 2022.
8
Natural Killer Cells and Dendritic Cells: Expanding Clinical Relevance in the Non-Small Cell Lung Cancer (NSCLC) Tumor Microenvironment.自然杀伤细胞与树突状细胞:在非小细胞肺癌(NSCLC)肿瘤微环境中的临床相关性不断拓展
Cancers (Basel). 2021 Aug 11;13(16):4037. doi: 10.3390/cancers13164037.
9
Systematic profiling of invasion-related gene signature predicts prognostic features of lung adenocarcinoma.侵袭相关基因特征的系统分析预测肺腺癌的预后特征。
J Cell Mol Med. 2021 May 31;25(13):6388-402. doi: 10.1111/jcmm.16619.
10
A bioinformatic analysis of the inhibin-betaglycan-endoglin/CD105 network reveals prognostic value in multiple solid tumors.生物信息学分析抑制素-β糖蛋白-内皮糖蛋白/CD105 网络在多种实体瘤中的预后价值。
PLoS One. 2021 Apr 5;16(4):e0249558. doi: 10.1371/journal.pone.0249558. eCollection 2021.
超越 PD-L1 标志物的肺癌免疫治疗。
Int J Mol Sci. 2019 Apr 18;20(8):1915. doi: 10.3390/ijms20081915.
4
Immunology of Plasmacytoid Dendritic Cells in Solid Tumors: A Brief Review.实体瘤中浆细胞样树突状细胞的免疫学:简要综述
Cancers (Basel). 2019 Apr 3;11(4):470. doi: 10.3390/cancers11040470.
5
Dendritic Cells and Cancer: From Biology to Therapeutic Intervention.树突状细胞与癌症:从生物学到治疗干预
Cancers (Basel). 2019 Apr 11;11(4):521. doi: 10.3390/cancers11040521.
6
Immune Cell Composition in Human Non-small Cell Lung Cancer.人类非小细胞肺癌中的免疫细胞组成。
Front Immunol. 2019 Feb 1;9:3101. doi: 10.3389/fimmu.2018.03101. eCollection 2018.
7
Tumor infiltrating mast cells determine oncogenic HIF-2α-conferred immune evasion in clear cell renal cell carcinoma.肿瘤浸润肥大细胞决定透明细胞肾细胞癌中致癌 HIF-2α 介导的免疫逃逸。
Cancer Immunol Immunother. 2019 May;68(5):731-741. doi: 10.1007/s00262-019-02314-y. Epub 2019 Feb 13.
8
Immune checkpoints and the regulation of tolerogenicity in dendritic cells: Implications for autoimmunity and immunotherapy.免疫检查点与树突状细胞耐受调节:自身免疫和免疫治疗的意义。
Autoimmun Rev. 2019 Apr;18(4):359-368. doi: 10.1016/j.autrev.2019.02.006. Epub 2019 Feb 8.
9
A radiogenomic dataset of non-small cell lung cancer.非小细胞肺癌的放射基因组数据集。
Sci Data. 2018 Oct 16;5:180202. doi: 10.1038/sdata.2018.202.
10
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.